Anticoagulants are medicines that reduce the blood's ability to form or extend clots by interfering with components of the coagulation system. They are used to prevent or treat conditions in which pathological clot formation poses a significant risk, including venous thromboembolism and selected forms of atrial fibrillation in which embolic stroke prevention is indicated. Anticoagulants differ from antiplatelet medicines, which primarily interfere with platelet activation and aggregation, and from thrombolytic medicines, which actively promote breakdown of established clots.
Anticoagulants include vitamin K antagonists, direct oral anticoagulants and injectable agents such as heparins. Their effects are not equivalent, and dosing, monitoring, onset, duration and reversal options vary. Because normal coagulation is essential for preventing bleeding after injury, reducing coagulation inevitably creates a potential bleeding risk. Treatment therefore requires balancing the probability and consequences of thrombosis against the probability and consequences of bleeding.
The coagulation system consists of interacting proteins that generate thrombin and ultimately convert fibrinogen into fibrin, producing a stabilised clot. Anticoagulants act at different points within this cascade. Vitamin K antagonists reduce synthesis of several vitamin K-dependent clotting factors, producing an anticoagulant effect that develops and resolves relatively slowly. Unfractionated and low-molecular-weight heparins enhance the activity of antithrombin, inhibiting key coagulation factors. Direct oral Anticoagulants include direct factor Xa inhibitors and direct thrombin inhibitors, which act more specifically on particular activated coagulation components. These mechanistic differences affect onset, half-life, interactions and laboratory monitoring. They also determine which reversal or supportive strategies may be considered when serious bleeding occurs.
Anticoagulants are used in both prevention and treatment. In venous thromboembolism, treatment reduces the likelihood that an existing thrombus will enlarge and that embolisation will occur, while preventive therapy may be used during periods of elevated clotting risk such as certain surgical or immobilisation settings. In atrial fibrillation, blood can stagnate in the atria and form thrombi that may embolise to the brain or other organs, and anticoagulation can substantially reduce this risk in appropriately selected people. Anticoagulants are also used in other cardiovascular and thrombotic circumstances. The duration of therapy varies because transient risk factors, persistent risk factors and recurrent events have different implications. Long-term treatment must be periodically reassessed because both thrombosis and bleeding risks change over time.
Monitoring requirements differ greatly among Anticoagulants. Vitamin K antagonists require regular measurement of the international normalised ratio because the therapeutic range is relatively narrow and blood concentrations can be influenced by diet, illness, liver function and many drug interactions. Many direct oral Anticoagulants have predictable pharmacokinetics and do not require routine coagulation testing to adjust every dose, although renal function, liver function, age, body size and adherence may still require assessment.
Heparin therapy can require laboratory monitoring in particular circumstances, depending on the formulation and clinical setting. The absence of routine monitoring for some medicines should not be interpreted as meaning that follow-up is unnecessary. Kidney function, bleeding history, interacting medicines and changes in clinical status can materially alter safety.
Bleeding is the principal adverse effect of Anticoagulants. It can range from minor bruising or nosebleeds to gastrointestinal bleeding or intracranial haemorrhage, with risk influenced by drug intensity, age, kidney function, previous bleeding, uncontrolled hypertension, interacting medicines and other factors. Signs of significant bleeding require urgent clinical assessment. Anticoagulants can also create procedural challenges because surgery and invasive procedures may require temporary interruption, bridging or alternative management depending on the thrombotic risk and the particular medicine. The decision to interrupt therapy cannot be based solely on fear of bleeding because stopping anticoagulation can increase the risk of serious thrombosis. Management therefore requires balancing competing risks rather than treating either bleeding or clotting risk in isolation.
Drug interactions are particularly important with Anticoagulants. Vitamin K antagonists interact with numerous prescription medicines, over-the-counter products and dietary factors. Direct oral Anticoagulants can be affected by medicines that alter transporter or hepatic enzyme activity. Other medicines that independently increase bleeding risk, including certain analgesic or antiplatelet agents, can compound anticoagulant-associated bleeding. Alcohol intake, acute illness and changes in kidney function can also affect risk depending on the medicine. Patients should generally ensure that clinicians and pharmacists know which anticoagulant they take, because treatment decisions involving new medicines or procedures may depend on its pharmacology and timing.
Anticoagulants should not be confused with medicines that dissolve existing clots. Anticoagulation generally prevents clot propagation and new clot formation while the body's endogenous fibrinolytic system gradually processes thrombus. Thrombolytic therapy is a different intervention used in selected time-critical situations where rapid clot dissolution is justified. Anticoagulation is also distinct from antiplatelet therapy, which is particularly important in arterial thrombosis involving platelet-rich clot formation. These mechanisms can overlap clinically, and some patients may receive more than one type of antithrombotic therapy, but combined treatment generally increases bleeding risk and therefore requires a specific indication.
The development of Anticoagulants has progressed from heparin and vitamin K antagonists to medicines with more targeted mechanisms and more predictable pharmacokinetics. Modern practice benefits from a wider range of options but also requires careful selection based on kidney function, indications, interactions, adherence, cost, access and reversal considerations. A common misconception is that anticoagulation makes blood “thin”; it does not literally reduce blood thickness but alters the coagulation process.
Another misconception is that bleeding risk means anticoagulants should be stopped whenever bleeding is feared. In reality, the clinical purpose is to maintain an appropriate balance between thrombosis prevention and bleeding risk. Correct use therefore depends on the specific indication, medicine, dose, duration and changing clinical circumstances.
